1. Barbaric M, Brooks E, Moore L, Cheifetz O. Effects of physical activity on cancer survival: a systematic review. Physiother Can 2010; 62:25– 34
2. Cheong I, Zhou S. Tumor-Specific Liposomal Drug Release Mediated By Liposomase. Methods Enzymol. 2009; 465: 251-65
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: Cancer J Clin2005; 55:74-108
4. Vinay K, Abbas A, Fauston N. Robbins and Cotran pathologic basis of disease. New York: Saunders. 2004.p.623-5.
5. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14:4300.
6. -Hajiani E, Masjedizadeh R, Hashemi J, Azmi M, Rajabi T. Risk factors for hepatocellular carcinoma in Southern Iran. Saudi Med J 2005; 26:974-7.
7. Colombo M, Choo Q, Del Ninno E, Dioguardi N, Kuo G, Donato M, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet. 1989; 334:1006-8.
8. Li M, Xiongzh G. Ion channels as targets for cancer therapy. Int J Physiol Pathophysiol Pharmacol 2011; 3(2):156-166.
9. Das M, Mohanty C, Sahoo SK. Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv 6(3): 285-304.
10. Poste G, Kirsh R. Site–Specific (Targeted) Drug Delivery in Cancer Therapy. Natuer Biotechnology 1983; 1: 869-78.
11. Tinsley R. Harrison, Braunwald E. Harrison’s Principles of Internal Medicine. 17th ed. New York: The McGraw-Hill Companies, Inc; 2008
12. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Cancer Letters 2008, 267(1): 133-64.
13. Zargari A. Medicinal Plants. Fifth Edition. Tehran University Press & Publishing Institute. 1375, third volume: 38-34
14. Bean Caitlin. Silybum marianum. st.3rd Nature conservancy, California, 785 Market floor. Sanfrancisco. 1985.
15. Iranian Pharmacopoeia Editing Committee. Iranian Pharmacopoeia. Ministry of Health and Medical Education Deputy of Food and Drug Administration. 2002, first edition.
16. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010; 24(10):1423-32. DOI: 10.1002/ptr.3207 PMID: 20564545
17. Varma PN, Talwar SK, Garg GP. Chemical Investigation of Silybum-Marianum. Plant Med. 1980;38(4):377-83. DOI: 10.1055/s-2008-1074893
18. Hackett ES, Twedt DC, Gustafson DL. Milk thistle and its derivative compounds: a review of opportunities for treatment of liver disease. J Vet Intern Med. 2013;27(1):10- 6. DOI: 10.1111/jvim.12002 PMID: 23140176
19. Venkataramanan, R., Ramachandran, V., Komoroski, B.J., Zhang, S., Schiff, P.L. and Strom, S.C., 2000. Milk thistle and herbal supplement decrease in the activity of CYP3A4 and uridine diphosphoglucuronosyl transfarase in human hepatocyte cultures. Drug Metabolism and Disposition, 28(11): 1270-1273.
20. Osuchoweski, M.F., Johson, V.J. and Sharma, R.P., 2004. Alteration in regional brain neurotransmitters by silymarin a natural antioxidant flavonoid mixture in BALB/c mice. Pharmaceutical Biology, 42(4-5): 384-389.
21. Dermarderosian, A, The review of Natural Products. Facts and Comparisons, Saint Louis, 2001: 722.
22. 22.Manna SK, Mukhopadhyay A, Van NT,Aggarwal BB. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis.J Immunol 1999; 163(12):6800-9.
23. 23.Okawa M, Kinjo J, Nohara T, Ono M. DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity of flavonoids obtained from some medicinal plants. Biol Pharm Bull 2001; 24 (10): 1202-5.
24. 24.Skottova N, Krecman V, Walterova D, Ulrichova J, Kosina P, Simanek V. Effect of silymarin on serum cholesterol level in rats. Acta Univ Palacki Olomuc Fac Med 1998; 141: 87-9.
25. Burgess CA. Silybum marianum (Milk Thistle). Journal of Pharmacy the Society of Winconsin 2003; 4: 3-40
26. Vogel G, Trost W, Braatz R, Odenthal KP, Brusewitz G, Antweiler H, Seeger R. Pharmacodynamics, site and mechanism of action of silymarin, the antihepatoxic principle from Silybum marianum (L.) Gaertn. 1. Acute toxicology or tolerance, general and specific (liver-) pharmacology. Arzneimittelforschung. 1975; 25 (1), 82-89.
27. Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology. 1996; 23: 749-54.
28. 64. Zi X, Mukhtar H, Agarwal R. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin:inhibition of mRNA expression of an endogenous tumor promoter TNF alpha. Biochem. Biophys. Res. Commun. 1997; 239: 334-9.
29. Zawang A, Langer R, Farokhzad O. Nanoparticle Delivery of Cancer Drugs. Annual Review of Medicine 2012; 63:185-98.
30. . Keller, B.C. (2001). Liposomes in nutrition. Trends Food Sci.Tech., 12(1),25-31.
31. Allen TM, Hansen CB, D E L. de Menezes. Pharmacokinetics of long-circulating liposomes. Adv Drug Deliv Rev 1995; 16(2): 267-84.
32. Sirisha, V N L et al. 2012. “Liposomes – the Potential Drug Carriers.” J Pharm 2(5): 26–38.
33. Clot p, Tabone N, Arico S, Albano E. Monitoring oxidative damage in patients with liver cirrhosis and different daily alcohol intake. Gut. 1994; 35: 1637 – 43.
34. Mourelle M, Muriel p, Favori L,franco T. prevention of CCl4 –induced liver cirrhosis by silymarin. Fundam. Clin. Pharmacol. 1989; 3: 183-91.
35. Letteron P, Labbe G, Degott C, Berson A, fromenty B, Delaforge M. Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Biochem. Pharmacol. 1990; 39: 2027 – 34.
36. Kohno H, Tanaka T, Kawabata K. Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int. J. Cancer. 2002; 101 (5): 461-8.
37. Invernizzi R, Bernuzzi S, Ciani D. Silymarine during maintenance therapy of acute promyelocytic leukemia. Haematologica. 1993; 78 (5): 340-1.
38. Grossmann M, Hoermann R, Weiss M. Spontaneous regression of hepatocellular carcinoma. Am. J. Gastroenterol. 1995; 90 (9): 1500-3.
39. Demark-Wahnefried, W., Robertson, C.N., Walther, P.J., Polascik, T.J., Paulson, D.F. and Vollmer, R.T., 2004. Pilot study to explore effects of low-fat, flaxseed-suplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology, 63(5): 900-904.
40. Nencini C, Giorgi G, Micheli L. Protevtive effect of silymarin on oxidative stress in rat brain. Phytomedicine 2007; 14: 129-35.
41. Haghiralsadat FA, Azhdari MA, Kalantar SM, Naderinezhad SA, Teymourizadeh KE, Yazdani MO, Hashemi MO, Daneshmand FA. Strategy of Improvements in the rapeutic index of medicinal herbs of Iranianin digenous: Synthesis and characterization of phospholipid lipid-based vesicles in corporated Trachyspermum copticum. SSU_Journals. 2016 Sep 15; 24(6):468-78. [Persian]
42. Majdizadeh M, Rezaei Zarchi S, Movahedpour AA, Shahi Malmir H, Sasani E, Haghiralsadat BF. A new strategy in improving therapeutic indexes of medicinal herbs: preparation and characterization of nano-liposomes containing Mentha piperita essential oil. J Shaeed Sdoughi Univ Med Sci Yazd. 2018;25(10):853–64. [Persian]
43. Karimi-Moghddam A, Nikounahad-Lotfabadi N, Haghiralsadat BF, Majdizadeh M. Investigating the effect of lipid nanoparticles containing silibinin anti-cancer drug on the growth of breast cancer MCF-7 cell line. Journal of Torbat Heydariyeh University of Medical Sciences. 2019;6(4):1-2. [Persian]
44. Soltani N, Nikoonahad lotfabadi N. Evaluation of the Effect of Niosomal Nano-Carriers Containing Rosemary (Rosemary officinalis) Essential oil on Survival of KG-1 Cell Line of Acute Myeloid Leukemia. sjimu. 2019; 27 (3) :162-172. [Persian]
45. Billah MM، Anthes JC. The regulation and cellular functions of phosphatidylcholine hydrolysis. Biochemical Journal. 1990;269(2):281-91.